The French CDMO Delpharm has acquired five manufacturing sites belonging to Famar, in France, Canada and the Netherlands.  
 
The transaction covers the French sites located in Orléans (Loiret), L’Aigle (Orne) and Saint-Rémy-sur-Avre (Eure-et-Loire), as well as the Montreal site in Canada and that of Bladel in the Netherlands.

The group of sites together represents a turnover of €250 million and 1,300 employees. Including the revenues of the five additional sites, Delpharm will generate €750 million in turnover.
 
“This acquisition by Delpharm, a reputable CDMO, represents a great opportunity for the 1300 Famar colleagues and will allow the sites to foresee a fruitful and sustainable future,” said Patrick Puy, president, Famar.

Sébastien Aguettant, president, Delpharm, said, “With a headcount of 4700 people working at 17 manufacturing sites, Delpharm is reaching a new level and is now part of the top five CDMOs worldwide.”